ATE429450T1 - Chimärische dr4 antikörper und ihre verwendung - Google Patents

Chimärische dr4 antikörper und ihre verwendung

Info

Publication number
ATE429450T1
ATE429450T1 AT00937844T AT00937844T ATE429450T1 AT E429450 T1 ATE429450 T1 AT E429450T1 AT 00937844 T AT00937844 T AT 00937844T AT 00937844 T AT00937844 T AT 00937844T AT E429450 T1 ATE429450 T1 AT E429450T1
Authority
AT
Austria
Prior art keywords
antibodies
chimeric
kits
diagnosis
articles
Prior art date
Application number
AT00937844T
Other languages
English (en)
Inventor
Avi Ashkenazi
Anan Chuntharapai
Kelly Dodge
Kyung Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE429450T1 publication Critical patent/ATE429450T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT00937844T 1999-05-28 2000-05-25 Chimärische dr4 antikörper und ihre verwendung ATE429450T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32287599A 1999-05-28 1999-05-28
PCT/US2000/014599 WO2000073349A1 (en) 1999-05-28 2000-05-25 Dr4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ATE429450T1 true ATE429450T1 (de) 2009-05-15

Family

ID=23256824

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00937844T ATE429450T1 (de) 1999-05-28 2000-05-25 Chimärische dr4 antikörper und ihre verwendung

Country Status (12)

Country Link
EP (2) EP2213302A3 (de)
JP (1) JP4589586B2 (de)
AT (1) ATE429450T1 (de)
AU (3) AU781952B2 (de)
CA (1) CA2374599A1 (de)
CY (1) CY1109151T1 (de)
DE (1) DE60042066D1 (de)
DK (1) DK1181319T3 (de)
ES (1) ES2325305T3 (de)
IL (1) IL146448A0 (de)
PT (1) PT1181319E (de)
WO (1) WO2000073349A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
DE69836956T2 (de) 1997-03-17 2007-10-31 Human Genome Sciences, Inc. Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
AU4817200A (en) * 1999-05-04 2000-11-17 Human Genome Sciences, Inc. Death domain containing receptor 5
PT1181319E (pt) * 1999-05-28 2009-07-14 Genentech Inc Anticorpos quiméricos contra dr4 e suas utilizações
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
AU2002256895B2 (en) * 2001-05-18 2008-09-18 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
CN100594935C (zh) * 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
PT1409544E (pt) 2001-07-03 2009-09-16 Genentech Inc Anticorpos de dr4 humanos e suas utilizações
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
JP2008503468A (ja) * 2004-06-18 2008-02-07 ジェネンテック・インコーポレーテッド Ａｐｏ２ｌレセプターアゴニストおよびｎｋ細胞活性化因子の使用方法
DE602005027848D1 (de) 2004-08-06 2011-06-16 Genentech Inc Tests und verfahren unter verwendung von biomarkern
RU2410438C2 (ru) 2004-08-06 2011-01-27 Дженентек, Инк. Анализы и способы, использующие биомаркеры
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2006083937A2 (en) 2005-02-02 2006-08-10 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
AU2006279618A1 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
JP2012526839A (ja) 2009-05-13 2012-11-01 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和分子
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
EP2736928B1 (de) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Gegen erbb3-gerichtete sur-bindende proteine
EP2793940B1 (de) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogatbindungsproteine
CN110305874A (zh) * 2019-06-19 2019-10-08 浙江省肿瘤医院 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
EP1012274B2 (de) * 1997-01-28 2011-06-15 Human Genome Sciences, Inc. "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
EP1860187B1 (de) * 1997-05-15 2011-07-13 Genentech, Inc. Apo-2-Rezeptor
PT1053256E (pt) * 1998-01-26 2011-09-28 Genentech Inc Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
ATE443723T1 (de) * 1998-06-12 2009-10-15 Genentech Inc Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
PT1181319E (pt) * 1999-05-28 2009-07-14 Genentech Inc Anticorpos quiméricos contra dr4 e suas utilizações

Also Published As

Publication number Publication date
WO2000073349A1 (en) 2000-12-07
AU2009201670A1 (en) 2009-05-21
PT1181319E (pt) 2009-07-14
AU2005201915A1 (en) 2005-06-02
AU781952B2 (en) 2005-06-23
DK1181319T3 (da) 2009-08-17
IL146448A0 (en) 2002-07-25
EP2213302A3 (de) 2010-11-03
CY1109151T1 (el) 2014-07-02
JP2003503017A (ja) 2003-01-28
EP2213302A2 (de) 2010-08-04
CA2374599A1 (en) 2000-12-07
EP1181319B1 (de) 2009-04-22
WO2000073349A9 (en) 2002-05-10
DE60042066D1 (de) 2009-06-04
ES2325305T3 (es) 2009-09-01
AU5296700A (en) 2000-12-18
AU2005201915B2 (en) 2009-01-22
JP4589586B2 (ja) 2010-12-01
EP1181319A1 (de) 2002-02-27

Similar Documents

Publication Publication Date Title
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
WO2004011611A3 (en) Taci antibodies and uses thereof
ATE252578T1 (de) 1,3-oxazolin- und 1,3-thiazolin-derivate, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
NO20061736L (no) Krystallform av epotilon B
ATE239797T1 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
ATE420097T1 (de) Substituierte sapogenine und ihre verwendung
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE529401T1 (de) Aminocyclohexylether-verbindungen und deren verwendung
NL1026892A1 (nl) ó1,8!Naftyridin-2-onen en verwante verbindingen voor de behandeling van schizofrenie.
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
ATE240326T1 (de) Pyrrolo-(3,2-b)pyridine und ihre verwendung als 5-ht1f agonisten
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
DE59706692D1 (de) Konjugat, geeignet zur bindung von substanzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1181319

Country of ref document: EP